Filgrastim Recruiting Phase 1 Trials for Acute Myeloid Leukemia (AML) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03263936Epigenetic Reprogramming in Relapse/Refractory AML
NCT03441048Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03467386Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia